Current strategies in immunotherapy for acute myeloid leukemia

被引:4
|
作者
Lichtenegger, Felix S. [1 ,2 ]
Schnorfeil, Frauke M. [1 ,3 ]
Hiddemann, Wolfgang [1 ,4 ]
Subklewe, Marion [1 ,3 ]
机构
[1] Klinikum Univ Munchen, Dept Internal Med 3, D-81377 Munich, Germany
[2] Klinikum Univ Munchen, Dept Internal Med 4, Div Clin Pharmacol, D-81377 Munich, Germany
[3] Helmholtz Inst Munich, Clin Cooperat Grp Immunotherapy, Munich, Germany
[4] Helmholtz Inst Munich, Clin Cooperat Grp Leukemia, Munich, Germany
关键词
acute myeloid leukemia; adoptive cellular therapy; chimeric antigen receptor; dendritic cell vaccination; gemtuzumab ozogamicin; immunotherapy; monoclonal antibody; peptide vaccination; TCR-transgenic; T cell; WT1 PEPTIDE VACCINATION; T-CELL RESPONSES; ACUTE MYELOGENOUS LEUKEMIA; TUMOR PROTEIN-1 WT1; DENDRITIC CELLS; GEMTUZUMAB OZOGAMICIN; COMPLETE REMISSION; STEM-CELLS; AML CELLS; MYELODYSPLASTIC SYNDROME;
D O I
10.2217/IMT.12.145
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The prognosis of acute myeloid leukemia, particularly when associated with adverse chromosomal or molecular aberrations, is poor due to a high relapse rate after induction chemotherapy. Postremission therapy for elimination of minimal residual disease remains a major challenge. Allogeneic hematopoietic stem cell transplantation has proven to provide a potent antileukemic effect. Novel strategies are needed for patients ineligible for this treatment. Here current immunotherapeutic concepts in acute myeloid leukemia in a nonallogeneic hematopoietic stem cell transplantation setting are reviewed. Data gathered with different monoclonal antibodies are discussed. Adoptive transfer of NK and T cells is reviewed, including evolving data on T-cell engineering. Results of systemic cytokine administration and of therapeutic vaccinations with peptides, modified leukemic cells and dendritic cells are presented. One particular focus of this review is the integration of currently running clinical trials. Recent immunotherapeutic studies have been encouraging and further interesting results are to be expected.
引用
收藏
页码:63 / 78
页数:16
相关论文
共 50 条
  • [1] Immunotherapy for acute myeloid leukemia: current trends, challenges, and strategies
    Chen, Evan C.
    Garcia, Jacqueline S.
    [J]. ACTA HAEMATOLOGICA, 2024, 147 (02) : 200 - 220
  • [2] The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies
    Chandra, Daniel J.
    Alber, Bernhard
    Saultz, Jennifer N.
    [J]. CANCERS, 2024, 16 (15)
  • [3] Current status of immunotherapy in acute myeloid leukemia
    Subklewe, Marion
    [J]. HEMASPHERE, 2018, 2 : 15 - 18
  • [4] Immunotherapy of Acute Myeloid Leukemia: Current Approaches
    Smits, Evelien L. J. M.
    Berneman, Zwi N.
    Van Tendeloo, Viggo F. I.
    [J]. ONCOLOGIST, 2009, 14 (03): : 240 - 252
  • [5] The progress and current status of immunotherapy in acute myeloid leukemia
    Yang, Dan
    Zhang, Xiuqun
    Zhang, Xuezhong
    Xu, Yanli
    [J]. ANNALS OF HEMATOLOGY, 2017, 96 (12) : 1965 - 1982
  • [6] The progress and current status of immunotherapy in acute myeloid leukemia
    Dan Yang
    Xiuqun Zhang
    Xuezhong Zhang
    Yanli Xu
    [J]. Annals of Hematology, 2017, 96 : 1965 - 1982
  • [7] Immunotherapy in Acute Myeloid Leukemia: A Literature Review of Emerging Strategies
    Guarnera, Luca
    Bravo-Perez, Carlos
    Visconte, Valeria
    [J]. BIOENGINEERING-BASEL, 2023, 10 (10):
  • [8] A perspective of immunotherapy for acute myeloid leukemia : Current advances and challenges
    Chen, Ying
    Wang, Jishi
    Zhang, Fengqi
    Liu, Ping
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [9] Current therapeutic strategies in the management of acute myeloid leukemia
    Fiegl, Michael
    Hiddemann, Wolfgang
    Braess, Jan
    [J]. MEDIZINISCHE KLINIK, 2007, 102 (04) : 309 - 316
  • [10] IMMUNOTHERAPY FOR ACUTE MYELOID LEUKEMIA
    HOCKER, P
    PITTERMANN, E
    LUTZ, D
    [J]. BLUT, 1976, 33 (03): : 195 - 195